InvestorsHub Logo
Followers 14
Posts 514
Boards Moderated 0
Alias Born 09/09/2017

Re: None

Monday, 03/01/2021 6:50:13 PM

Monday, March 01, 2021 6:50:13 PM

Post# of 232888
Experienced Bio-Investor Question: Does anyone know how common it is for the FDA to request the "raw data" of a Phase 3 clinical study as soon as it's available?

If it's a fairly common practice, then fine.

If it is not common, why would the FDA do this? Do they have a lot of statisticians on the payroll that break down raw data in parallel with Amarex? Seems like a duplication of effort, so is there another reason for requesting raw data, something the FDA can do but Amarex can't?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News